Revenue
2017
2018
2019
2020
2021
ONCOLYTICS BIOTECH INC (ONCY)
Price—Loading quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $0 | $547,707 | $6.2M | — | — |
| Research & development | $21.6M | $17.7M | $15.4M | $12.9M | $12.9M | $10.8M | $10.0M | $9.4M | $9.8M | $8.6M |
| Operating expenses | — | — | $11.5M | $13.3M | $12.5M | $9.6M | $7.2M | $6.2M | $5.5M | $5.3M |
| Operating income | −$35.0M | −$33.8M | −$26.9M | −$26.2M | −$25.5M | −$20.4M | −$17.3M | −$15.6M | −$15.3M | −$13.9M |
| EBITDAderived | −$34.9M | −$33.7M | −$26.8M | −$26.1M | −$25.4M | −$20.3M | −$17.2M | −$15.5M | −$15.1M | −$13.7M |
| Net income | −$31.7M | −$27.8M | −$24.8M | −$26.3M | −$22.5M | −$33.1M | −$17.0M | −$15.6M | −$15.1M | −$13.7M |
| Basic EPSper diluted share | -CA$0.41 | -CA$0.41 | -CA$0.43 | -CA$0.49 | -CA$0.56 | -CA$1.50 | -CA$1.06 | -CA$1.12 | -CA$1.20 | -CA$0.12 |
| Diluted EPSper diluted share | -CA$0.41 | -CA$0.41 | -CA$0.43 | -CA$0.49 | -CA$0.56 | -CA$1.50 | -CA$1.06 | -CA$1.12 | -CA$1.20 | -CA$0.12 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 12, 2026Form 4 | Kelly JaredChief Executive Officer | BuyCommon Shares | 5.0K | $0.96 | $4.8K | 114.0K |
| Mar 11, 2026Form 4 | Parsons James T.Director | BuyCommon Shares | 10.0K | $1.03 | $10.3K | 41.8K |
| Feb 12, 2026Form 4 | Seizinger Bernd R.Director | BuyCommon Shares | 40.0K | $0.85 | $34.0K | 567.0K |
| Feb 12, 2026Form 4 | Pisano WayneDirector | BuyCommon Shares | 30.0K | $0.84 | $25.2K | 492.4K |
| Feb 12, 2026Form 4 | Look KirkChief Financial Officer | BuyCommon Shares | 12.0K | $0.84 | $10.1K | 287.5K |